KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE)
KBIO
KBIO was delisted on the 16th of December, 2015.
43 hedge funds and large institutions have $39.8M invested in KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) in 2014 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 11 increasing their positions, 14 reducing their positions, and 18 closing their positions.
10% less funds holding
Funds holding: 48 → 43 (-5)
21% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 14
24% less capital invested
Capital invested by funds: $52.2M → $39.8M (-$12.4M)
28% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$2.49M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$800K |
| 3 |
Renaissance Technologies
New York
|
+$462K |
| 4 |
SIM
SSI Investment Management
Los Angeles,
California
|
+$213K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$179K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$4.59M |
| 2 |
CCP
Clough Capital Partners
Boston,
Massachusetts
|
-$1.09M |
| 3 |
WC
Wexford Capital
West Palm Beach,
Florida
|
-$847K |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$628K |
| 5 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$481K |
KBIO Hedge Fund Activity: Q2 2014 in Review
43 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) (KBIO) for Q2 2014, worth a combined $39.8M — down 24% from $52.2M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of KBIO and 13 opened new positions — a net loss of 5 holders — while 14 trimmed existing stakes and 11 added.
The largest buyer was BVF Inc, opening a new position worth an estimated $2.49M. The largest seller was JP Morgan Chase, exiting entirely with an estimated $4.59M sold.
- 43 institutional investors held KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) (KBIO) as of Q2 2014, down from 48 in Q1 2014.
- Funds reported $39.8M of KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) stock for Q2 2014, down 24% quarter-over-quarter.
- 13 funds opened new KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) positions in Q2 2014 and 18 closed out, a net change of -5 holders.
- The largest KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) buyer in Q2 2014 was BVF Inc, an estimated $2.49M added.
- The largest KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) seller in Q2 2014 was JP Morgan Chase, an estimated $4.59M sold.
Based on aggregated 13F filings for Q2 2014.